Abstract
Abstract
Effectiveness of corona virus disease-19 (COVID-19) vaccines used in India is unexplored and need to be substantiated. The present case-control study was planned to elicit the effectiveness of COVID-19 vaccines in preventing infection and disease severity in the general population of Bihar, India. This case-control study was conducted among people aged ≥45 years during April to June 2021. The cases were the COVID-19 patients admitted or visited All India Institute of Medical Sciences (AIIMS), Patna, Bihar, India, and were contacted directly. The controls were the individuals tested negative for severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) at the Virology laboratory, AIIMS-Patna and contacted telephonically for collection of relevant information. The vaccine effectiveness (VE) was calculated by using the formula (VE = 1 – odds ratio). The adjusted VE for partial and full vaccination were estimated to be 52.0% (95% confidence interval (CI) 39.0–63.0%) and 83.0% (95% CI 73.0–89.0%) respectively for preventing SARS CoV-2 infection. The sub-group analyses of the cases have shown that the length of hospital stays (LOS) (partially vaccinated: 9 days vs. unvaccinated: 12 days; P = 0.028) and the severity of the disease (fully vaccinated: 30.3% vs. partially vaccinated: 51.3% and unvaccinated: 54.1%; P = 0.035) were significantly low among vaccinated compared to unvaccinated individuals. To conclude, four out of every five fully vaccinated individuals are estimated to be protected from contracting SARS CoV-2 infection. Vaccination lowered LOS and chances of development of severe disease.
Publisher
Cambridge University Press (CUP)
Subject
Infectious Diseases,Epidemiology
Reference31 articles.
1. Case-Control Study of the Effectiveness of the 2010-2011 Seasonal Influenza Vaccine for Prevention of Laboratory-Confirmed Influenza Virus Infection in the Korean Adult Population
2. 22. Comprehensive Guidelines for Management of COVID-19 patients (2021) Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India.
3. 20. OpenEpi – Sample Size for Unmatched Case-Control Studies. Available at https://www.openepi.com/SampleSize/SSCC.htm (Accessed 18 April 2021).
4. 3. Ella, R , (2021) Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial. Infectious Diseases (except HIV/AIDS), 2021 Jul. Available at http://medrxiv.org/lookup/doi/10.1101/2021.06.30.21259439 (Accessed 11 July 2021).
5. Age-Related Vulnerability to Coronavirus Disease 2019 (COVID-19): Biological, Contextual, and Policy-Related Factors
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献